PRLD · NASDAQ
Prelude Therapeutics (PRLD) Stock Price & Fundamentals
Prelude Therapeutics (PRLD) closed at $572.93 on Oct 9, 2026, down 1.01% from the previous close of $578.80.
Share price, past year
1Y +6.52%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $572.93 |
| Sep 30, 2026 | $579.19 |
| Aug 31, 2026 | $593.44 |
| Jul 31, 2026 | $569.42 |
| Jun 30, 2026 | $552.40 |
| May 29, 2026 | $545.97 |
| Apr 30, 2026 | $557.33 |
| Mar 31, 2026 | $530.74 |
| Feb 27, 2026 | $543.71 |
| Jan 30, 2026 | $550.29 |
| Dec 31, 2025 | $534.42 |
| Nov 28, 2025 | $544.70 |
| Oct 31, 2025 | $542.31 |
Key statistics
- Market cap
- $45.72B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.73
- Revenue (TTM)
- $22.42M
- Net income (TTM)
- −$60.49M
- Shares outstanding
- 79.8M
- Dividend yield
- —
- 52-week range
- $513.86 – $608.36
Prelude Therapeutics's market cap is $45.72B, based on a share price of $572.93 and 79.8M shares outstanding as of Aug 6, 2026.
Financials
Prelude Therapeutics reported revenue of $12.14M for fiscal 2025, up 73.43% from fiscal 2024.
Prelude Therapeutics reported a net loss of $99.50M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $12.14M | +73.4% | −$99.50M | −819.6% | −$1.29 | −$56.37M |
| FY2024ended Dec 31, 2024 | $7.00M | — | −$127.17M | −1,816.8% | −$1.68 | −$103.65M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $5.70M | −$13.92M | −$0.14 |
| Q1 FY2026ended Mar 31, 2026 | $4.58M | −$10.39M | −$0.13 |
| Q4 FY2025ended Dec 31, 2025 | $5.64M | −$16.46M | −$0.20 |
| Q3 FY2025ended Sep 30, 2025 | $6.50M | −$19.73M | −$0.26 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$31.23M | −$0.41 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$32.09M | −$0.42 |
| Q3 FY2024ended Sep 30, 2024 | $3.00M | −$32.27M | −$0.43 |
Company profile
- Name
- Prelude Therapeutics Inc
- Ticker
- PRLD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 175 Innovation Boulevard, Wilmington, DE 19805
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001678660
Recent SEC filings
- Sep 10, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jun 10, 2026
- May 12, 2026
- May 12, 2026
- Apr 21, 2026
- Apr 20, 2026
Frequently asked questions
What is Prelude Therapeutics's stock price?
Prelude Therapeutics (PRLD) closed at $572.93 on Oct 9, 2026, down 1.01% from the previous close of $578.80.
What is Prelude Therapeutics's market cap?
Prelude Therapeutics's market cap is $45.72B, based on a share price of $572.93 and 79.8M shares outstanding as of Aug 6, 2026.
How much revenue does Prelude Therapeutics make?
Prelude Therapeutics reported revenue of $12.14M for fiscal 2025, up 73.43% from fiscal 2024.
Does Prelude Therapeutics pay a dividend?
Prelude Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Prelude Therapeutics Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures